{
Eurofins Scientific S.E. A

Companies

}
001122334455554433221100
001122334455554433221100

health sector shows resilience amid potential us tariffs on pharmaceuticals

In Paris, the health sector shows resilience as Eurofins Scientific and Sanofi rise amid a downbeat CAC 40, unaffected by upcoming U.S. tariffs set for April 2025. However, UBS warns that the sector may still face challenges, including potential additional tariffs from Trump targeting pharmaceuticals. Sartorius Stedim Biotech sees a decline, reflecting concerns over U.S. sales exposure and tariff implications.
bourse.fortuneo.fr
Euro MedinCell S.A. Sartorius Stedim Biotech S.A. Sanofi Eurofins Scientific S.E. A Ipsen S.A. FRA USA Charles Weston Donald Trump Show more
Finance & Economy, Market Report
11:33 03.04.2025

analysts update recommendations and price targets for key european stocks

Analysts have made several notable recommendations, including JP Morgan maintaining an Underweight rating for Adecco with a reduced target of CHF 19.60, while Air France-KLM was downgraded by Barclays to Underweight with a target of EUR 7. ArgenX received a buy rating from HC Wainwright & Co, raising its target to 717 USD, and BioMérieux was upgraded to Outperform by Oddo BHF with a target of EUR 132. Other significant changes include upgrades for Deliveroo and Orange, while OVH Groupe remains a sell with a raised target of EUR 8.50.
Zonebourse
British Pound Sterling Danish Krone Swiss Franc Euro United States Dollar Ørsted A/S JD Sports Fashion Plc Axon Partners Group, S.A. Teleperformance SE Assystem S.A. OVH Groupe Transgene SA Just Eat Takeaway.com N.V. Swiss Re AG Edenred SE HelloFresh SE La Francaise des Jeux SA Vivendi SE UBS Group AG Orange S.A. Bureau Veritas SA Geberit AG BELIMO Holding AG Watches of Switzerland Group PLC JCDecaux SE Michelin Adecco Group AG Air France-KLM argenx SE SGS SA Cargotec Oyj Deliveroo plc Gecina Eurofins Scientific S.E. A Bufab AB Delivery Hero SE bioMérieux Sika AG FRA DEU CHE GBR DNK USA SWE Show more
Business & Industry, Market Report
08:48 15.01.2025

global clinical biomarkers market projected to reach 47 billion by 2031

The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
openPR.com
Eurofins Scientific S.E. A PerkinElmer Inc Johnson & Johnson Services Inc. Bio-Rad Laboratories, Inc. Qiagen N.V. Merck KGaA Thermo Fisher Scientific Inc. General Electric Co Siemens Healthineers AG Agilent Technologies, Inc. F. Hoffmann-La Roche Ltd. USA Show more
Healthcare, Market Report
08:45 16.12.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.